Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proactive therapeutic drug monitoring of infliximab for perianal fistulising Crohn's disease
ACTRN12621000023853Phase 4Not yet recruiting
- Sponsor
- Associate Professor Susan Connor
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in Crohn's disease and anal fistula (2 arms), sponsored by Associate Professor Susan Connor. Primary endpoint: Fistula healing. Planned start May 2021; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on ACTRN12621000023853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000023853.